170 related articles for article (PubMed ID: 23638745)
41. CDX-1401 combined with TLR agonist: positive phase 1 results.
Riedmann EM
Hum Vaccin Immunother; 2012 Dec; 8(12):1742. PubMed ID: 23980263
[No Abstract] [Full Text] [Related]
42. Combination strategies for enhancing the efficacy of immunotherapy in cancer patients.
Moschella F; Proietti E; Capone I; Belardelli F
Ann N Y Acad Sci; 2010 Apr; 1194():169-78. PubMed ID: 20536466
[TBL] [Abstract][Full Text] [Related]
43. TLR ligand-peptide conjugate vaccines: toward clinical application.
Zom GG; Khan S; Filippov DV; Ossendorp F
Adv Immunol; 2012; 114():177-201. PubMed ID: 22449782
[TBL] [Abstract][Full Text] [Related]
44. Toll-like receptor-agonists in the treatment of skin cancer: history, current developments and future prospects.
Wenzel J; Tormo D; Tüting T
Handb Exp Pharmacol; 2008; (183):201-20. PubMed ID: 18071661
[TBL] [Abstract][Full Text] [Related]
45. Triggering of toll-like receptor signaling pathways in T cells contributes to the anti-tumor efficacy of T cell responses.
Salem ML
Immunol Lett; 2011 Jun; 137(1-2):9-14. PubMed ID: 21352854
[TBL] [Abstract][Full Text] [Related]
46. Use of human MonoMac6 cells for development of in vitro assay predictive of adjuvant safety in vivo.
Zaitseva M; Romantseva T; Blinova K; Beren J; Sirota L; Drane D; Golding H
Vaccine; 2012 Jul; 30(32):4859-65. PubMed ID: 22609036
[TBL] [Abstract][Full Text] [Related]
47. Anticancer TLR agonists on the ropes.
Guha M
Nat Rev Drug Discov; 2012 Jun; 11(7):503-5. PubMed ID: 22743965
[No Abstract] [Full Text] [Related]
48. Type I interferons as vaccine adjuvants against infectious diseases and cancer.
Bracci L; La Sorsa V; Belardelli F; Proietti E
Expert Rev Vaccines; 2008 Apr; 7(3):373-81. PubMed ID: 18393607
[TBL] [Abstract][Full Text] [Related]
49. Toll-like receptor signaling in anti-cancer immunity.
Okamoto M; Sato M
J Med Invest; 2003 Feb; 50(1-2):9-24. PubMed ID: 12630564
[TBL] [Abstract][Full Text] [Related]
50. The adjuvant effect of TLR agonists on CD4(+) effector T cells is under the indirect control of regulatory T cells.
Olivier A; Sainz-Perez A; Dong H; Sparwasser T; Majlessi L; Leclerc C
Eur J Immunol; 2011 Aug; 41(8):2303-13. PubMed ID: 21538349
[TBL] [Abstract][Full Text] [Related]
51. Trial watch: Toll-like receptor ligands in cancer therapy.
Le Naour J; Kroemer G
Oncoimmunology; 2023; 12(1):2180237. PubMed ID: 36875550
[TBL] [Abstract][Full Text] [Related]
52. Toll-like receptor agonists in cancer therapy.
Adams S
Immunotherapy; 2009 Nov; 1(6):949-64. PubMed ID: 20563267
[TBL] [Abstract][Full Text] [Related]
53. Vaccine adjuvants as potential cancer immunotherapeutics.
Temizoz B; Kuroda E; Ishii KJ
Int Immunol; 2016 Jul; 28(7):329-38. PubMed ID: 27006304
[TBL] [Abstract][Full Text] [Related]
54. Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN.
Ahonen CL; Doxsee CL; McGurran SM; Riter TR; Wade WF; Barth RJ; Vasilakos JP; Noelle RJ; Kedl RM
J Exp Med; 2004 Mar; 199(6):775-84. PubMed ID: 15007094
[TBL] [Abstract][Full Text] [Related]
55. Rational peptide-based tumour vaccine development and T cell monitoring.
Scheibenbogen C; Letsch A; Schmittel A; Asemissen AM; Thiel E; Keilholz U
Semin Cancer Biol; 2003 Dec; 13(6):423-9. PubMed ID: 15001161
[TBL] [Abstract][Full Text] [Related]
56. Cancer relapse under chemotherapy: why TLR2/4 receptor agonists can help.
Garay RP; Viens P; Bauer J; Normier G; Bardou M; Jeannin JF; Chiavaroli C
Eur J Pharmacol; 2007 Jun; 563(1-3):1-17. PubMed ID: 17383632
[TBL] [Abstract][Full Text] [Related]
57. Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia.
Spaner DE; Masellis A
Leukemia; 2007 Jan; 21(1):53-60. PubMed ID: 17066089
[TBL] [Abstract][Full Text] [Related]
58. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
[TBL] [Abstract][Full Text] [Related]
59. Developments in anticancer vaccination: budding new adjuvants.
Santos-Sierra S
Biol Chem; 2020 Mar; 401(4):435-446. PubMed ID: 31782943
[TBL] [Abstract][Full Text] [Related]
60. Triggering of Toll-like Receptors in Old Individuals. Relevance for Vaccination.
Zareian N; Aprile S; Cristaldi L; Ligotti ME; Vasto S; Farzaneh F
Curr Pharm Des; 2019; 25(39):4163-4167. PubMed ID: 31713478
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
